Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 2/20 | 0.33 |
| ▸ | FKBP1A | P62942 | 4/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15681469 | 0.88 | HMGCR (0.41) | HMGCRMEN1ALDH1A1KMT2AAPOBEC3A | |
| SCHEMBL10187705 | 0.85 | HMGCR (0.40) | HMGCRMEN1ALDH1A1KMT2AAPOBEC3A | |
| SCHEMBL15889341 | 0.85 | HMGCR (0.39) | HMGCRMEN1ALDH1A1KMT2AAPOBEC3A | |
| SCHEMBL17088137 | 0.83 | HMGCR (0.40) | HMGCRMEN1ALDH1A1KMT2AAPOBEC3A | |
| SCHEMBL14997741 | 0.82 | HMGCR (0.39) | HMGCRMEN1ALDH1A1KMT2AAPOBEC3A | |
| SCHEMBL9945786 | 0.80 | HMGCR (0.37) | HMGCRMEN1ALDH1A1KMT2AAPOBEC3A | |
| SCHEMBL25701430 | 0.75 | CYP19A1 (0.41) | ALDH1A1 | |
| SCHEMBL12263816 | 0.74 | HMGCR (0.35) | HMGCRMEN1ALDH1A1KMT2ANAAA | |
| SCHEMBL14191887 | 0.74 | ALDH1A1 (0.36) | HMGCRALDH1A1NAAAFKBP1A | |
| SCHEMBL15113827 | 0.73 | HMGCR (0.30) | HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124313-B2 | Resist composition, method of forming resist pattern, novel compound, and acid generator | TOKYO OHKA KOGYO CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-20100121077-A1 | RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, NOVEL COMPOUND, AND ACID GENERATOR | TOKYO OHKA KOGYO CO., LTD. (JP) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121077-A1 | RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, NOVEL COMPOUND, AND ACID GENERATOR | RER1, ABCC1, SLC11A2 | HMGCR 3565/4885MEN1 41/4885ALDH1A1 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.